Section of Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Department of Rheumatology, Skane University Hospital Malmö, Inga Marie Nilssons gata 32, S-205 02, Malmö, Sweden.
Arthritis Res Ther. 2017 Oct 24;19(1):237. doi: 10.1186/s13075-017-1446-2.
Altered microbial composition of the intestine, commonly referred to as dysbiosis, has been associated with several autoimmune diseases including primary Sjögren's syndrome (pSS). The aims of the current study were to study the intestinal microbial balance in pSS and to identify clinical features associated with dysbiosis.
Forty-two consecutive pSS patients and 35 age-matched and sex-matched control subjects were included in the study in an open clinic setting. Stool samples were analyzed for intestinal dysbiosis using a validated 16S rRNA-based microbiota test (GA-map™ Dysbiosis Test; Genetic Analysis, Oslo, Norway). Dysbiosis and severe dysbiosis were defined in accordance with the manufacturer's instructions. Patients were evaluated with regard to disease activity (European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI)). In addition, patients were examined for laboratory and serological features of pSS as well as fecal calprotectin levels. Furthermore, patients were investigated regarding patient-reported outcomes for pSS (EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)) and irritable bowel syndrome (IBS)-like symptoms according to the Rome III criteria.
Severe dysbiosis was more prevalent in pSS patients in comparison to controls (21 vs 3%; p = 0.018). Subjects with pSS and severe dysbiosis had higher disease activity as evaluated by the ESSDAI total score (13 vs 5; p = 0.049) and the ClinESSDAI total score (12 vs 5; p = 0.049), lower levels of complement component 4 (0.11 vs 0.17 g/L; p = 0.004), as well as higher levels of fecal calprotectin (110 vs 33 μg/g; p = 0.001) compared to the other pSS patients. In contrast, severe dysbiosis among pSS patients was not associated with disease duration, IBS-like symptoms, or the ESSPRI total score.
Severe intestinal dysbiosis is a prevalent finding in pSS and is associated both with clinical and laboratory markers of systemic disease activity as well as gastrointestinal inflammation. Further studies are warranted to elucidate a potential causative link between dysbiosis and pSS.
肠道微生物组成的改变,通常称为肠道菌群失调,与几种自身免疫性疾病有关,包括原发性干燥综合征(pSS)。本研究的目的是研究 pSS 患者的肠道微生物平衡,并确定与菌群失调相关的临床特征。
在开放诊所环境中,纳入 42 例连续的 pSS 患者和 35 名年龄和性别匹配的对照者。使用经过验证的 16S rRNA 微生物组测试(GA-map™ 菌群失调测试;遗传分析,奥斯陆,挪威)分析粪便样本中的肠道菌群失调。根据制造商的说明定义菌群失调和严重菌群失调。评估患者的疾病活动度(欧洲抗风湿病联盟(EULAR)干燥综合征疾病活动指数(ESSDAI)和临床 ESSDAI(ClinESSDAI))。此外,还检查了患者的 pSS 实验室和血清学特征以及粪便钙卫蛋白水平。此外,根据罗马 III 标准,还调查了患者的 pSS 患者报告结局(EULAR 干燥综合征患者报告指数(ESSPRI))和肠易激综合征(IBS)样症状。
与对照组相比,pSS 患者严重菌群失调更为常见(21% vs 3%;p=0.018)。严重菌群失调的 pSS 患者 ESSDAI 总分(13 分 vs 5 分;p=0.049)和 ClinESSDAI 总分(12 分 vs 5 分;p=0.049)更高,补体成分 4 水平更低(0.11 vs 0.17 g/L;p=0.004),粪便钙卫蛋白水平更高(110 vs 33 μg/g;p=0.001),而其他 pSS 患者则无此表现。相反,pSS 患者的严重菌群失调与疾病持续时间、IBS 样症状或 ESSPRI 总分无关。
严重的肠道菌群失调在 pSS 中较为常见,与系统性疾病活动的临床和实验室标志物以及胃肠道炎症均有关。需要进一步的研究来阐明菌群失调与 pSS 之间的潜在因果关系。